Peptide News Digest

#Hair-Loss

2 stories

Industry · View digest

Kimberly-Clark Says Rogaine Sales Are Up 30% This Year and Points to GLP-1 Hair Loss as a Possible Reason

Kimberly-Clark, which has completed its acquisition of Tylenol and Band-Aid owner Kenvue, reported a 30% year-to-date increase in sales of Rogaine hair-loss medication, CNBC reported on November 5. CEO Michael Hsu suggested the growth could be driven by adoption of GLP-1 drugs, which carry hair loss as a potential side effect. He offered it as a possible explanation, not a measured one.

Industry · View digest

Drug Discovery News Feature: 'Can Hair Loss Be the Next GLP-1 Moment?' Surveys Peptide and Small-Molecule Pipeline

A Drug Discovery News feature surveyed the emerging hair loss treatment landscape and asked whether the category could replicate the GLP-1 obesity drug breakout. Lead candidates include Pelage Pharmaceuticals' PP405 (small-molecule topical, Phase 3 launch 2026 with FDA approval potentially 2027-2029), the MLPH peptide (preclinical, novel safe mechanism for both sexes), the APN5 peptide (Korean research team, hair growth + suppression of loss), and product launches from Ouai Haircare's $50 Bond Repair Balm and Omi Well Beauty's Hair Growth Peptides expanding the consumer category.